Debate before you decide. Every morning, MorningRounds distills the latest research, approvals, and guideline updates — then gives you the tools to challenge, debate, and validate patient-specific decisions with specialty AI experts. Each recommendation is grounded in the evidence, so physicians and care teams can make transparent, defensible calls.
The National Cancer Institute opened a funding opportunity supporting precision-oncology research and biomarker-driven treatment programs at designated cancer centers.
Read update →NCCN published revised colorectal cancer guidelines with updated surveillance intervals and expanded biomarker-testing recommendations for early-stage disease.
Read update →The FDA cleared a new targeted therapy for a common solid-tumor driver mutation, expanding biomarker-matched options for previously treated patients.
Read update →Short conversations with the clinicians behind the briefing — the week's research, approvals, and trials, talked through for the drive in.
For each case, MorningRounds could automatically assemble and compare the authoritative sources that matter:
Then your AI physician panel debates where these sources agree, where they differ, and why — giving the treating physician a transparent, evidence-backed rationale rather than a single AI-generated answer.
The result is a platform significantly more comprehensive than relying on any single guideline source.
Morning Rounds connects the full AIM One Health suite so the briefing isn't where the work stops — it's where it starts. The tools that fit your role are surfaced first.
Surgical Oncology is the flagship edition. The same daily-briefing model — research, approvals, trials, and connected platforms — rolls out across every surgical specialty.
Clinicians, patients, and administrators read the same source of truth — each in the view that fits them — connected to the platforms that move the work forward.